5 Subtyping Questions for Matthew J.C. Ellis, MB BChir, PhD
December 4th 2012For the past 10 years, Matthew J.C. Ellis, MB BChir, PhD, has focused his research on exploring the breast cancer genome in partnerships with academic and government-funded centers in the United States and the United Kingdom.
New Data on Horizon in Several Key Areas
December 3rd 2012Although new therapies have revolutionized the management of certain hematologic malignancies during the past 15 years, clinical trials currently under way hold the potential to yield new targeted agents and better treatment strategies.
Bevacizumab PFS Benefit Extends Across Cohorts in AURELIA Trial
November 20th 2012An exploratory analysis of the phase III AURELIA trial demonstrated that adding bevacizumab (Avastin) to chemotherapy in patients with platinum-resistant ovarian cancer benefited patients across treatment cohorts.
Pomalidomide Meets Primary PFS Endpoint
November 20th 2012A data safety monitoring board (DSMB) has found that a phase III study of pomalidomide, an oral immunomodulatory agent, met its primary endpoint by demonstrating a significant improvement in progression-free survival for patients with multiple myeloma (MM).
Evolution of Targeted Therapy: GIST Experience Points the Way to Defining Third-Line Treatment
November 19th 2012Targeted antineoplastic therapy based on the presence of a well-defined molecular target should be recognized as a standard-of-care approach in an increasing number of clinical settings.